Exact Sciences joins the Alliance
This month, we’re excited to welcome Exact Sciences as the newest member of the Alliance.
About Exact Sciences
Exact Sciences is molecular diagnostics company focused on the early detection and prevention of colorectal cancer with its non-invasive screening product, Cologuard. Exact Sciences estimates that 3 million people have used Cologuard since it was launched, resulting in the detection of 14,000 early-stage cancers and 98,000 pre-cancerous polyps. Exact Sciences is now expanding its detection screening to address liver cancer, for which there are an estimated 3 million high-risk Americans.
Published: November 4, 2019